Contact this trialFirst, we need to learn more about you.
EZH2 Inhibitor
Tazemetostat for Sarcoma
Recruiting1 awardPhase 2
Montreal, Quebec
This trial is testing a new drug, tazemetostat, to see if it is effective in treating different types of solid tumors. There are 8 cohorts of subjects, each with a different type of tumor. The subjects will be given tazemetostat for 28 days, and then their response will be assessed. Treatment will continue until disease progression, unacceptable toxicity, or the subject withdraws from the study.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service